Markets:

Overview

News

Currencies

International

Treasuries

Johnson & Johnson (NY:JNJ)

240.87 +2.54 (+1.07%)

Official Closing Price Updated: 7:00 PM EDT, Jun 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

You'll Never Guess Which Healthcare Stock Delivered the Best First-Quarter Performance in the S&P 500. ↗

April 07, 2026

Could this player be heading into a new era of growth?

Via The Motley Fool

Robotic Revolution in the Electrophysiology Lab: FDA Clears Stereotaxis Synchrony System

April 06, 2026

ST. LOUIS – April 6, 2026 – In a milestone that signals a paradigm shift for cardiac care, Stereotaxis (NYSE American: STXS) has received FDA 510(k) clearance for its Synchrony™ System. The approval...

Via MarketMinute

Topics Artificial Intelligence

Stereotaxis Secures FDA Clearance for Synchrony™ System, Completing Its Vision for the Robotic "Digital Cockpit"

April 06, 2026

ST. LOUIS — April 6, 2026 — Stereotaxis (NYSE: STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias and other endovascular procedures, announced today that...

Via MarketMinute

Johnson & Johnson (NYSE:JNJ) Stands Out as a Quality Dividend Stock for Reliable Income ↗

April 01, 2026

Via Chartmill

The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports

April 06, 2026

In a move that has sent shockwaves through the global healthcare industry, the U.S. Administration officially finalized a sweeping new trade policy on April 6, 2026, imposing 100% tariffs on branded...

Via MarketMinute

Topics Economy World Trade

Gilead Extends Tender Offer for Arcellx as Biotech M&A Sentiment Faces a Reality Check

April 06, 2026

Gilead Sciences (NASDAQ: GILD) announced a strategic extension of its tender offer to acquire cell therapy innovator Arcellx (NASDAQ: ACLX) on April 1, 2026. Originally scheduled to expire on April 2,...

Via MarketMinute

Better Healthcare Stock to Own in a Recession: Defensive or Growth? ↗

April 04, 2026

The answer to the question might surprise many investors. It pays to be open-minded about risk.

Via The Motley Fool

Topics Economy Energy

JEPI vs. JEPQ: Which Is the Better Buy in April? ↗

April 04, 2026

These two high-yield heavyweights offer very different approaches.

Via The Motley Fool

Topics Bonds ETFs Economy

Comparing 2 Healthcare Giants: Which Dividend Aristocrat Will Keep Paying Out for Generations to Come?

April 03, 2026

Johnson & Johnson offers scale and stability, but Abbott’s cheaper valuation, higher yield, and stronger upside make it the more attractive pick now.

Via Barchart.com

Med-Tech Resilience: AngioDynamics Pivot Pays Off with Double-Digit Growth and Profitability

April 02, 2026

The medical technology sector has long been a bellwether for the health of the broader economy and the efficiency of the healthcare system. Today, April 2, 2026, AngioDynamics (NASDAQ:ANGO) provided...

Via MarketMinute

Topics Economy Retirement

This Healthcare Stock Barely Flinches During Market Sell-Offs ↗

April 02, 2026

Shares of Johnson & Johnson have fallen by less than 2% over the past month, while the S&P 500 has fallen by more than 7%.

Via The Motley Fool

Topics Economy Stocks

Stagflation Fears Are Back: These 3 Stocks Can Help You Ride Out the Storm ↗

April 02, 2026

These blue-chip stocks can make investors money if stagflation returns -- and also if it doesn't.

Via The Motley Fool

Topics Economy

The New Blue-Chip: How Johnson & Johnson Refined Its Empire for a High-Growth Future

April 01, 2026

As we enter the second quarter of 2026, Johnson & Johnson (NYSE: JNJ) stands as a starkly different entity than the consumer-facing conglomerate that defined the 20th century. Having successfully shed...

Via Finterra

Topics Artificial Intelligence Earnings Economy

Volatility Is Spiking. Here Are 3 Dividend Stocks You Can Buy Without Hesitation. ↗

April 01, 2026

These dividend stocks are ones you can rest peacefully at night owning.

Via The Motley Fool

Topics Economy

The Dividend King That's Raised Its Payout for 63 Consecutive Years ↗

March 31, 2026

This healthcare leader can weather almost any storm.

Via The Motley Fool

Topics Intellectual Property

Deep Dive: Boston Scientific (BSX) and the New Era of Medical Device Dominance

March 31, 2026

Date: March 31, 2026 Introduction Boston Scientific Corporation (NYSE: BSX) finds itself at a critical crossroads this morning. After a year of record-breaking growth and the successful launch of its...

Via Finterra

Topics Lawsuit Product Recall

1 Reason Eli Lilly Stock Is Still a Buy ↗

March 28, 2026

Eli Lilly is much more than just a weight loss stock.

Via The Motley Fool

Topics Artificial Intelligence

Is Intuitive Surgical a Buy Right Now? ↗

March 27, 2026

The healthcare leader has seen better times.

Via The Motley Fool

Topics World Trade

2 Stocks I Plan to Hold for the Next 20 Years ↗

March 27, 2026

These companies help me sleep peacefully at night.

Via The Motley Fool

Topics Intellectual Property

A Q2 2026 Playbook for Navigating Market Uncertainty ↗

March 26, 2026

Via MarketBeat

What You Need To Know Ahead of Johnson & Johnson's Earnings Release

March 26, 2026

Johnson & Johnson is expected to announce its first-quarter results next month, and analysts are projecting a single-digit decline in its EPS.

Via Barchart.com

Topics ETFs

The 15-Minute Breakthrough: A Deep Dive into GH Research (GHRS) and the Future of Rapid-Acting Psychedelics

March 26, 2026

Today’s Date: March 26, 2026 Introduction As the global mental health crisis reaches unprecedented levels, the pharmaceutical industry has been forced to look beyond traditional SSRIs toward more...

Via Finterra

Topics Cannabis Initial Public Offering Intellectual Property

The Fear Gauge Ascendant: VIX Hits 26 as Geopolitical Storms and 'Higher-for-Longer' Reality Grip Markets

March 24, 2026

The CBOE Volatility Index (VIX), Wall Street’s premier measure of expected stock market volatility, climbed to a reading of 26.15 this week, marking its highest sustained level in nearly two years. As...

Via MarketMinute

Topics Derivatives Economy Stocks

If You Only Own Tech Stocks, Jim Cramer Has a Blunt Warning for You in 2026 ↗

March 23, 2026

CNBC commentator Jim Cramer sees value in the artificial intelligence (AI) realm beyond the technology sector.

Via The Motley Fool

Topics Artificial Intelligence Economy Stocks

FDA Approves Protagonist’s ICOTYDE: The Oral Peptide Revolution Hits the Psoriasis Market

March 23, 2026

In a landmark decision for the dermatology sector, the U.S. Food and Drug Administration (FDA) has officially approved ICOTYDE™ (icotrokinra), a first-of-its-kind oral peptide for the treatment of...

Via MarketMinute

1 Dividend ETF That Could Turn $500 Monthly Into a $725,000 Portfolio That Pays $21,750 Annually ↗

March 20, 2026

Patience can pay off with this high-yield dividend ETF.

Via The Motley Fool

Topics ETFs

Johnson & Johnson-Protagonist Therapeutics Partnered New Psoriasis Pill Wins FDA Nod, Shakes Up Competition With AbbVie ↗

March 19, 2026

FDA approves Icotyde, a once-daily psoriasis pill from Johnson & Johnson, sparking new competition in treatment options.

Via Benzinga

2 Reasons to Buy Johnson & Johnson Stock Like There's No Tomorrow ↗

March 19, 2026

This stock is one to own during any market environment.

Via The Motley Fool

Topics Artificial Intelligence

AbbVie Shares Retreat to Multi-Month Lows Amid Competitive Headwinds and Technical Breakdown

March 18, 2026

The pharmaceutical giant AbbVie (NYSE: ABBV) experienced a sharp decline on Wednesday, March 18, 2026, as its stock price tumbled to its lowest level since mid-2025. Shares of the Illinois-based...

Via MarketMinute

Topics ETFs Economy Intellectual Property

The High-Stakes Gambit: How Healthcare Giants are 'Front-Loading' Megadeals to Outrun Regulatory Storms

March 18, 2026

In the face of the most aggressive antitrust environment in decades and the sweeping legislative changes of the 2025 "One Big Beautiful Bill Act" (OBBBA), the healthcare sector has not retreated from...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.